{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Test identifies Lynch syndrome for targeted cancer monitoring: Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC","html":"","width":"100%","height":180,"duration":1115,"description":"Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide cancer surveillance for patients and their families.\n(00:32)\n Would each of you share a little bit about yourselves and your background? Dr. Shen?\n \n(01:25)\n Rihanna, could we have you give a little background about yourself as well?\n \n(01:48)\n Could you provide us with an overview of Lynch syndrome?\n \n(03:44)\n Can you expand on why genetic testing for Lynch syndrome is so important?\n \n(06:03)\n Who would benefit from Lynch testing?\n \n(07:51)\n Is Lynch syndrome the only type of inherited predisposition to colon cancer?\n \n(08:48)\n Does the healthcare provider order these tests, and what kind of samples should be considered in these patients?\n \n(10:50)\n Are there any limitations to the types of variants that can be detected by this test? And how does Mayo Clinic Laboratories ensure comprehensive results for patients?\n\n(14:24)\n How are the results used in patient care?\n \n(16:33)\n Could you summarize the benefits of these tests and of doing them at Mayo Clinic Laboratories?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}